SIRAKOSS
SIRAKOSS is a Scotland-based medical device company that develops synthetic bone graft substitutes. It is an innovative medical device company developing synthetic bone graft substitutes for trauma, spine, craniomaxillofacial and dental applications. Based in Scotland, SIRAKOSS is developing granular and putty forms of their proprietary MaxSi(TM) Graft technology.
SIRAKOSS
Industry:
Biopharma Health Care Life Science Medical Medical Device Wellness
Founded:
2010-01-01
Address:
Edinburgh, Edinburgh, City Of, United Kingdom
Country:
United Kingdom
Website Url:
http://www.sirakoss.com
Total Employee:
1+
Status:
Active
Contact:
(754) 518-6410
Email Addresses:
[email protected]
Total Funding:
4.8 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail ReCAPTCHA V2 JustHost DNS
Current Employees Featured
Founder
Investors List
Scottish Investment Bank
Scottish Investment Bank investment in Series A - Sirakoss
Epidarex Capital
Epidarex Capital investment in Series A - Sirakoss
Official Site Inspections
http://www.sirakoss.com
- Host name: dedserv4081.levonline.com
- IP address: 217.70.37.81
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
More informations about "Sirakoss"
OssDsign
Next generation orthobiologics products. OssDsign is a developer and global provider of next generation orthobiologics products. Based on cutting edge material science, the company …See details»
Sustainability - OssDsign AB - sirakoss.com
Every year our products are helping more patients around the world to achieve a better quality of life. As a supplier of medical products that have the possibility to profoundly touch people’s …See details»
Management Team - OssDsign AB - sirakoss.com
CTO since 2024, previously VP, Strategy and Business Development since 2021. Born: 1972 Education and experience: Tom has over 20 years’ commercial and technical Board and …See details»
Sirakoss Company Profile 2024: Valuation, Investors, Acquisition ...
When was Sirakoss founded? Sirakoss was founded in 2010. Where is Sirakoss headquartered? Sirakoss is headquartered in Dundee, United Kingdom. What is the size of Sirakoss? Sirakoss …See details»
Sirakoss - Products, Competitors, Financials, Employees, …
Sirakoss is a medical device company that develops synthetic bone graft substitutes. On November 3, 2020 Sirakoss was acquired by OssDsign. Use the CB Insights Platform to …See details»
Sirakoss - Contacts, Employees, Board Members, Advisors & Alumni
SIRAKOSS is a Scotland-based medical device company that develops synthetic bone graft substitutes.See details»
Karolinska Development's portfolio company OssDsign enters
Nov 4, 2020 Sirakoss Ltd is a privately held Scottish company that has developed Osteo 3 ZP Putty, a nanosynthetic bone graft substitute designed to provide surgeons with an easy-to-use, …See details»
Sirakoss Company Profile - Office Locations, Competitors ... - Craft
Sirakoss is a company that provides bone grafting solutions to surgeons. Its products enable the delivery of bone healing in patients. Sirakoss's product, Osteo3, is a nanosynthetic bone graft …See details»
OssDsign completes acquisition of bone graft company Sirakoss
Jan 18, 2021 OssDsign has completed the acquisition of Sirakoss, and the transaction was announced on November 3, 2020. The Magazine Advertising About Us ... expands by …See details»
History - OssDsign AB - sirakoss.com
In November 2020, the company expanded into Orthobiologics through the acquisition of Sirakoss Ltd, who had developed a next generation nanosynthetic bone graft substitute designed to …See details»
Sirakoss acquisition | ONE
Nov 5, 2020 Sirakoss has successfully developed Osteo3 ZP Putty, a nanosynthetic bone graft substitute to facilitate bone repair, which recently received 510(k) marketing clearance from …See details»
Epidarex Capital Portfolio Company Sirakoss Acquired By Ossdsign
Nov 3, 2020 Sirakoss has successfully developed Osteo 3 ZP Putty, a nanosynthetic bone graft substitute to facilitate bone repair, which recently received 510(k) marketing clearance from …See details»
OssDsign completes acquisition of the Scottish bone graft …
Nov 9, 2020 OssDsign AB (publ) has today completed the previously announced acquisition of Sirakoss Ltd. The transaction was announced in a press release on November 3, 2020. …See details»
Epidarex Capital Portfolio Company SIRAKOSS Acquired by …
Epidarex Capital led the 2014 Series A and subsequent financings of Sirakoss following its spin-out from the University of Aberdeen. In October, the lead program of Epidarex Capital portfolio …See details»
Board of Directors - OssDsign AB - sirakoss.com
Board member since 2024. Born: 1965 Education and experience: Christer Fåhraeus has thirty years of experience as CEO, board member, and chairman from fast-growing listed and …See details»
Bone graft company spun out from University research acquired …
Nov 6, 2020 Sirakoss was spun out from the University of Aberdeen in 2011 and has now been acquired by OssDsign, a leading bone-regeneration company based in Sweden. Synthetic …See details»
OssDsign acquires Sirakoss, enters USD 4 billion bone graft market
Nov 3, 2020 OssDsign acquires all outstanding Sirakoss shares in an all-cash transaction, which is subject to customary closing conditions. The purchase price of USD 11 million, not including …See details»
'Game-changing' technology in post-bone graft healing gets FDA …
Jun 17, 2020 Sirakoss secured a CE mark for its Osteo 3 bone graft substitute in February 2019 — a development that Buckland described as a “tremendously important step” in validating the …See details»
CEO statement - OssDsign AB - sirakoss.com
OssDsign is a fast-growing developer and provider of next generation orthobiologics products. Based on cutting edge material science, we develop and market products that support the …See details»
SIRAKOSS Receives U.S. FDA 510 (k) Clearance for Osteo
Jun 17, 2020 SIRAKOSS was spun out of the University of Aberdeen in 2011 based on the research of Professor Iain Gibson and is supported through financing from Epidarex Capital …See details»